July 12, 2024
Leanna Standish
IV CURCUMIN
AIMS Institute’s integrative oncology team is investigating the therapeutic effects of intravenous curcumin in treating the most aggressive type of brain cancer, called glioblastoma. Curcumin is the molecule present in turmeric root that has anticancer activity. Curcumin has been shown in cell culture experiments to cause the programmed death of glioblastoma cells. We use IV curcumin in order to provide sufficient levels of curcumin to the brain that will slow tumor growth. Our brain cancer patients are enrolled in AIMS Institute’s IRB-approved study called the AIMS CANCER OUTCOMES STUDY. Last year we presented our first results of IV curcumin in glioblastoma to the SWEDISH HOSPITAL NEUROLOGY SEMINAR and at the ONCOLOGY ASSOCIATION OF NATUROPATHIC ONCOLOGY annual meeting.
Currently, Drs. Jaffe, Anthony, and Standish are preparing a scientific manuscript for a medical journal that summarizes our findings.
LIQUID BIOPSY IS NOW AVAILABLE FOR BRAIN CANCER
AIMS Institute utilizes cutting-edge cancer genetic sequencing to help us understand the unique biology of each patient’s cancer. Liquid biopsy refers to a blood test that sequences the DNA in tumor cells that circulate in the blood. Until 2024 there has never been a liquid biopsy for brain cancer. Thanks to BILLION TO ONE a cancer gene company there is now a blood test for brain cancer. These blood tests help us know what the best treatment might be and also whether the current treatment is working for the patient.
